MedTrace Logo

Korean Post-marketing Surveillance for Orencia®

NCT01583244 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 701

Last updated 2016-05-12

No results posted yet for this study

Summary

The purpose of this post-marketing surveillance is to investigate and confirm the type and incidence of newly identified adverse events and any other factors affecting safety and efficacy of Orencia® so that the regulatory authority can manage the marketing approval properly.

Conditions

Interventions

DRUG

No Intervention (subjects were previously treated with Orencia®)

No Intervention

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-03-31
Primary Completion
2016-02-29
Completion
2016-02-29

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01583244 on ClinicalTrials.gov